Evaluation of novel highly specific antibodies to cancer testis antigen Centrin‐1 for radioimmunoimaging and radioimmunotherapy of pancreatic cancer

Evaluation of novel highly specific antibodies to cancer testis antigen Centrin‐1 for radioimmunoimaging and radioimmunotherapy of pancreatic cancer

Abstract Background Pancreatic ductal adenocarcinoma (PDAC) accounts for >90% of pancreatic malignancies, and has median survival of <6 months. There is an urgent need for diagnostic and therapeutic options for PDAC. Centrin1 (CETN1) is a novel member of Cancer/Testis Antigens, with a 25‐fold...

Full description

Bibliographic Details
Main Authors: Rubin Jiao, Kevin J. H. Allen, Mackenzie E. Malo, Muath Helal, Zewei Jiang, Karishma Smart, Susan V. Buhl, David Rickles, Ruth A. Bryan, Ekaterina Dadachova
Format: Article
Language:English
Published: Wiley 2019-09-01
Series:Cancer Medicine
Subjects:
177Lutetium
213Bismuth
centrin1
pancreatic adenocarcinoma
radioimmunotherapy
SPECT/CT imaging
Online Access:https://doi.org/10.1002/cam4.2379

Internet

https://doi.org/10.1002/cam4.2379

Similar Items